Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
The invention provides methods of treatment of non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine, such as CV-8972 and CV-8814.
1. A method of treating non-obstructive hypertrophic cardiomyopathy (HCM) in a subject, the method comprising providing to a subject having non-obstructive HCM a compound represented by formula (X):
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the subject has at least one symptom selected from the group consisting of angina, atrial fibrillation, dizziness, fainting, fatigue, heart palpitation, leg swelling, light-headedness, shortness of breath, and stroke.
3. The method of claim 1 , wherein the compound is provided in a pharmaceutical composition.
4. The method of claim 3 , wherein the pharmaceutical composition is provided orally.
5. The method of claim 4 , wherein the composition comprises a format selected from the group consisting of a tablet, troche, lozenge, aqueous suspension, oily suspension, emulsion, hard capsule, soft capsule, and syrup.
6. The method of claim 3 , wherein the pharmaceutical composition comprises a mixture of the compound and an erodible polymer that promotes swelling of the mixture in an aqueous environment.
7. The method of claim 6 , wherein the erodible polymer is hydroxypropyl methylcellulose (HPMC).
8. The method of claim 7 , wherein the mixture comprises the compound and HMPC in a weight ratio of from about 1:10 to about 10:1.
9. The method of claim 3 , wherein the pharmaceutical composition is a unit dosage comprising from about 10 mg to about 500 mg of the compound.
10. The method of claim 3 , wherein the pharmaceutical composition comprises a crystal comprising a Form A polymorph of the compound.
11. The method of claim 10 , wherein the crystal comprises a hydrochloride salt of the compound.